News

Anti-EBV trial results explained by Professor Michael Pender

About the Anti-EBV clinical trial

A treatment to target EBV has been shown to improve symptoms in some people with progressive MS in a world-first clinical trial.

The small phase I safety trial used an ‘adoptive T cell immunotherapy’ treatment. This involves taking blood from patients, extracting their immune cells, and then ‘training’ these cells in the lab to recognise and destroy EBV. The cells are then reintroduced to the patient’s body and go to work in targeting the EBV hiding in the body.

The trial was carried out by Professor Michael Pender and Professor Rajiv Khanna and MS Research Australia is proud to have contributed to the funding of this project, as well as significantly supporting Professor Pender’s EBV research over the last decade.

In this video Professor Pender explains how the trial came about, what it involved and what the results may mean for the future.

About Professor Michael Pender

Professor Michael Pender is a neurologist and researcher from The University of Queensland and Royal Brisbane and Women’s Hospital. He has spent much of his career investigating EBV in MS with a great deal of support along the way from MS Research Australia.

About AHSCT – current thinking

There have been recent positive steps forward for people with MS considering AHSCT. Read the current thinking towards AHSCT for people with MS.

Research conferences: shaping the future of MS

CEO Rohan Greenland gives an update on the MS Australia activities for October, focusing on the world's largest MS research conference ECTRIMS and the importance of conferences in shaping the future of MS.

Sarah’s tribute to MS research

In 2015 Sarah's life changed completely when she was diagnosed with multiple sclerosis, she is now on a mission to raise funds to power MS research.

Does “MS fatigue” capture the symptom experience?

The International Progressive MS Alliance has recently highlighted that very little progress has been made in treating and understanding MS fatigue.

DMTs: Impact of access on quality of life

MS Australia's advocacy efforts have contributed to a number of subsidised MS medications and disease-modifying therapies (DMTs). New research now shows the effect this has on the outcomes for people living with MS in New Zealand.

Submissions: an important advocacy tool

As part of our advocacy work at MS Australia, we make many submissions each year, to various Australian Government inquiries and consultations.

What us to keep you in the loop? Subscribe today!

  • Enter your details
Read More
Anti-EBV trial promising for progressive MSsex hormones in MS

Newsletter subscription

  • Enter your details

Anti-EBV trial results explained by Professor Michael Pender